← All trials
NCT03065660
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2017
- Primary completion
- Aug 1, 2019
- Completion date
- Aug 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 710
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of BirminghamLead sponsor
- University of BirminghamOverall official - principal investigator
- City Hospitals Sunderland NHS Foundation TrustCollaborator
- University of EdinburghCollaborator
- University of NottinghamCollaborator
- University of WarwickCollaborator
- University of OxfordCollaborator
- University of LiverpoolCollaborator
- University of LeedsCollaborator
- Moorgreen Hospital, SouthamptonCollaborator
- University of LondonCollaborator
- University of ManchesterCollaborator
- University of MelbourneCollaborator
- University of BirminghamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.